Quantinno Capital Management LP Raises Stock Position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Quantinno Capital Management LP raised its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 58.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 185,399 shares of the medical instruments supplier’s stock after buying an additional 68,591 shares during the period. Quantinno Capital Management LP owned about 0.09% of DENTSPLY SIRONA worth $3,519,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Pacer Advisors Inc. grew its holdings in shares of DENTSPLY SIRONA by 15,105.1% in the fourth quarter. Pacer Advisors Inc. now owns 4,503,591 shares of the medical instruments supplier’s stock worth $85,478,000 after acquiring an additional 4,473,972 shares during the period. Nuance Investments LLC grew its stake in shares of DENTSPLY SIRONA by 25.0% during the 4th quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier’s stock valued at $257,103,000 after purchasing an additional 2,708,097 shares during the period. Norges Bank purchased a new stake in shares of DENTSPLY SIRONA during the 4th quarter valued at about $45,730,000. AQR Capital Management LLC increased its position in shares of DENTSPLY SIRONA by 245.1% during the 4th quarter. AQR Capital Management LLC now owns 2,893,023 shares of the medical instruments supplier’s stock valued at $54,389,000 after purchasing an additional 2,054,767 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of DENTSPLY SIRONA by 18.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier’s stock worth $238,186,000 after purchasing an additional 1,975,404 shares during the period. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Trading Up 1.2%

Shares of XRAY opened at $16.70 on Monday. The firm has a market cap of $3.33 billion, a P/E ratio of -8.07, a price-to-earnings-growth ratio of 1.80 and a beta of 0.92. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.25 and a quick ratio of 0.84. DENTSPLY SIRONA Inc. has a 1 year low of $12.16 and a 1 year high of $28.44. The company has a 50 day simple moving average of $14.41 and a two-hundred day simple moving average of $17.30.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.14. The company had revenue of $879.00 million during the quarter, compared to analysts’ expectations of $854.75 million. DENTSPLY SIRONA had a negative net margin of 10.59% and a positive return on equity of 12.62%. DENTSPLY SIRONA’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period last year, the company posted $0.42 earnings per share. On average, equities analysts expect that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 11th. Investors of record on Friday, March 28th were given a $0.16 dividend. The ex-dividend date of this dividend was Friday, March 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 3.83%. DENTSPLY SIRONA’s dividend payout ratio is currently -14.10%.

Analyst Ratings Changes

A number of analysts have commented on XRAY shares. StockNews.com raised shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Piper Sandler reduced their price objective on DENTSPLY SIRONA from $20.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, April 30th. Wells Fargo & Company lowered their target price on DENTSPLY SIRONA from $20.00 to $19.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Robert W. Baird cut their price target on DENTSPLY SIRONA from $22.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, February 28th. Finally, Mizuho decreased their price objective on DENTSPLY SIRONA from $21.00 to $18.00 and set a “neutral” rating on the stock in a research note on Thursday, March 13th. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $20.36.

Insider Buying and Selling

In other news, Director Gregory T. Lucier purchased 15,142 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was acquired at an average price of $16.51 per share, for a total transaction of $249,994.42. Following the acquisition, the director now directly owns 81,971 shares of the company’s stock, valued at $1,353,341.21. This represents a 22.66% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.50% of the stock is owned by company insiders.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.